USPTO Examiner JAFFRI ZEHRA - Art Unit 3771

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18420909STENT DEVICE WITH STENT COVERING WITH REGIONS OF DIFFERING POROSITYJanuary 2024January 2025Allow1210YesNo
18382907BARBED ROD FOR LINEAR TISSUE CLOSURE AND APPROXIMATIONOctober 2023August 2024Allow1010YesNo
18282070LIGATION CLIP INCLUDING FLEXIBLE INSERT ASSEMBLYSeptember 2023June 2025Allow2100YesNo
18154129MEDICAL INSTRUMENT SET, DELIVERY SYSTEM, AND EMBOLIC DEVICE DELIVERY MEDICAL SYSTEMJanuary 2023May 2025Abandon2801NoNo
18075164ULTRASONIC SCALPELDecember 2022February 2024Allow1410YesNo
18049059OPTICALLY CLEAVED CATHETER COILING SYSTEMOctober 2022March 2025Allow2911YesNo
17966779MEDICAL INSTRUMENTOctober 2022March 2025Allow3010YesNo
17936418MEDICAL INSTRUMENT SET, DELIVERY SYSTEM, AND EMBOLIC DEVICE DELIVERY MEDICAL SYSTEMSeptember 2022April 2025Abandon3101NoNo
17913205MENISCAL REPAIR DELIVERY DEVICESeptember 2022April 2025Allow3011YesNo
17896309TWISTER IMPLANT DETACHMENT MECHANISMAugust 2022January 2025Allow2901YesNo
17885618TREATMENT INSTRUMENTAugust 2022October 2024Abandon2620YesNo
17885278ULTRASOUND TREATMENT TOOLAugust 2022January 2025Allow2930YesNo
17707130SYSTEMS AND METHODS FOR EMBOLIC IMPLANT DEPLOYMENTMarch 2022June 2025Abandon3840YesNo
17695209ENDOVASCULAR COIL DEVICE FOR EMBOLIZATION OF BLOOD VESSELSMarch 2022February 2024Abandon2310YesNo
17685197FLEXIBLE FEATURE FOR EMBOLIC IMPLANT DEPLOYMENTMarch 2022February 2024Allow2420YesNo
17638588TISSUE ANCHOR AND RELATED METHODSFebruary 2022December 2024Allow3410NoNo
17677963VASO-OCCLUSIVE DEVICE AND DELIVERY ASSEMBLYFebruary 2022October 2024Allow3210YesNo
17673098STENT DEVICE WITH STENT COVERING WITH REGIONS OF DIFFERING POROSITYFebruary 2022October 2023Allow2010YesNo
17671054BARBED ROD FOR LINEAR TISSUE CLOSURE AND APPROXIMATIONFebruary 2022September 2023Allow1910NoNo
17627716PACIFIERJanuary 2022October 2024Allow3310YesNo
17569620Delivery and Detachment System Imposing a Friction Force on a Securement Wire to Minimize Movement of an Implantable Intravascular DeviceJanuary 2022October 2024Allow3311YesNo
17566287IMPLANT DETACHMENT SYSTEMS WITH A MODIFIED PULL WIREDecember 2021June 2023Allow1800YesNo
17564764SYSTEMS AND METHODS FOR EMBOLIC IMPLANT DEPLOYMENTDecember 2021January 2025Abandon3631YesNo
17564914PULL WIRE DETACHMENT FOR INTRAVASCULAR DEVICESDecember 2021September 2024Allow3311YesNo
17558691METHODS FOR CLOSING A WOUNDDecember 2021September 2024Allow3330YesNo
17551039Knotless Locking Device with Directional Tensioning and LockingDecember 2021December 2023Abandon2410NoNo
17540057Re-Tensionable Suture Anchor System and Related MethodsDecember 2021April 2024Allow2820NoNo
17453037MEDICAL SYSTEMS, DEVICES, AND RELATED METHODSNovember 2021February 2024Allow2720YesNo
17447396SUTURE PASSING DEVICESeptember 2021December 2023Abandon2710YesNo
17436835HYDRAULIC MEDICAL INSTRUMENT AND SURGERY ASSISTING ROBOTSeptember 2021March 2024Allow3000YesNo
17407331SOFT ANCHORS HAVING INCREASED ENGAGEMENT BETWEEN DEPLOYMENT SUTURES AND SLEEVEAugust 2021April 2023Allow2000YesNo
17428069SURGICAL INSTRUMENT AND OPERATION ROBOTAugust 2021February 2025Allow4310NoNo
17384726Mechanical Detachment SystemsJuly 2021January 2025Abandon4210NoNo
17351295SHEET-SHAPED OBJECT ATTACHING DEVICEJune 2021September 2024Abandon3901NoNo
17323578METHOD AND APPARATUSES FOR ACCESSING AND/OR MODIFYING A TARGET PATIENT TISSUE SITEMay 2021January 2024Allow3200YesNo
17293226SYSTEMS AND METHODS OF ENDOSCOPIC INSTRUMENTS WITH ARTICULATING ENDMay 2021April 2025Abandon4711NoNo
17306412LEAFLET GRASPING AND CUTTING DEVICEMay 2021March 2024Allow3511YesNo
17285517VITRECTOME ACTUATORApril 2021March 2025Allow4740NoNo
17272943OPERATION SYSTEM, SURGICAL SYSTEM, OPERATION INSTRUMENT, MEDICAL DEVICE, AND EXTERNAL FORCE DETECTION SYSTEMMarch 2021September 2024Abandon4210NoNo
17273050DUAL-MOTOR CLIP APPLICATORMarch 2021March 2025Abandon4920NoNo
17191613PRE-SHAPED TISSUE ANCHORS AND NEEDLES FOR TISSUE ANCHOR DEPLOYMENTMarch 2021December 2024Abandon4520NoNo
17190964TREATMENT DEVICEMarch 2021November 2024Allow4420YesNo
17271464A DELIVERY SYSTEM FOR IMPLANTING A MEDICAL DEVICEFebruary 2021September 2024Allow4310YesNo
17270901A fault-tolerant endovascular inflation deviceFebruary 2021July 2024Abandon4010NoNo
17270343FLUID FLOW METAL SLEEVEFebruary 2021April 2024Allow3820YesNo
17155585DEVICES, SYSTEMS, AND METHODS FOR OTOLOGYJanuary 2021March 2025Allow5021YesNo
16965849EAR TREATMENT INSTRUMENTJanuary 2021June 2024Abandon4610NoNo
17260578A SUTURE MEMBER, SUTURING NEEDLE AND SUTURING DEVICEJanuary 2021February 2025Allow4940NoNo
17119549MEDICAL TREATMENT TOOLDecember 2020October 2024Abandon4720NoNo
16976659PROSTHETIC DEVICE ADHESIVE SYSTEMAugust 2020June 2024Allow4630NoNo
17000289DEVICE SET DESIGNED FOR PCNL SURGERYAugust 2020June 2024Allow4640YesNo
16947202DEVICE AND METHOD FOR TREATMENT OF HEMORRHOIDSJuly 2020January 2024Allow4220YesYes
16802077RETENTION ANCHOR FOR SURGICAL ACCESS DEVICESFebruary 2020December 2024Allow5740YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JAFFRI, ZEHRA.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
1
(100.0%)
Not Allowed After Appeal Filing
0
(0.0%)
Filing Benefit Percentile
99.7%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner JAFFRI, ZEHRA - Prosecution Strategy Guide

Executive Summary

Examiner JAFFRI, ZEHRA works in Art Unit 3771 and has examined 52 patent applications in our dataset. With an allowance rate of 67.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner JAFFRI, ZEHRA's allowance rate of 67.3% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by JAFFRI, ZEHRA receive 1.48 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by JAFFRI, ZEHRA is 33 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +48.0% benefit to allowance rate for applications examined by JAFFRI, ZEHRA. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 35.7% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 59% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 20% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 99% percentile among all examiners. Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 5% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 41% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 41% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.